Highlights
- Market Cap
- $682.06M
- Enterprise Value
- $644.21M
- EPS (TTM)
- -$1.85
- Gross Profit (TTM)
- -$1.26M
- EBITDA (TTM)
- -$172.18M
- Year Range
- $2.41 - $8.72
- Target Price
- $12.50
- ROA (TTM)
- -74.97%
- ROE (TTM)
- -96.84%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Solid Biosciences Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
Solid Biosciences Inc. (SLDB) has returned 27.66% so far this year and 94.59% over the past 12 months.
Solid Biosciences Inc.
- 1D
- 10.94%
- 1M
- 15.94%
- YTD
- 27.66%
- 6M
- 16.69%
- 1Y
- 94.59%
- 3Y*
- 14.95%
- 5Y*
- -38.46%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Jan 26, 2018, SLDB's average daily return is +0.07%, while the average monthly return is +1.46%. At this rate, your investment would double in approximately 4.0 years.
Historically, 43% of months were positive and 57% were negative. The best month was Dec 2020 with a return of +129.0%, while the worst month was Mar 2018 at -74.1%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 9 months.
On a daily basis, SLDB closed higher 44% of trading days. The best single day was Oct 1, 2020 with a return of +70.4%, while the worst single day was Nov 12, 2019 at -74.4%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 14.54% | -3.87% | 15.94% | 27.66% | |||||||||
| 2025 | -20.50% | 75.79% | -33.81% | -10.54% | -3.02% | 51.71% | 40.45% | -19.88% | 12.59% | -12.64% | 0.74% | 3.87% | 41.00% |
| 2024 | 12.21% | 36.28% | 41.85% | -33.41% | -6.88% | -31.36% | 57.32% | 0.11% | -21.95% | -20.80% | 3.26% | -29.82% | -34.85% |
| 2023 | 40.89% | -25.86% | -15.66% | 2.95% | 26.64% | -15.21% | -17.75% | -16.24% | -30.19% | -11.51% | 26.46% | 117.73% | 14.13% |
| 2022 | -30.29% | -33.23% | 47.31% | -53.33% | 1.79% | 8.00% | 9.65% | -5.19% | -27.09% | -8.42% | 4.52% | -19.70% | -79.50% |
| 2021 | -13.98% | 22.24% | -30.61% | -7.96% | -25.34% | -3.68% | -23.77% | -2.87% | -11.81% | -15.06% | -13.79% | 0.00% | -76.91% |
Benchmark Metrics
Solid Biosciences Inc. has an annualized alpha of 4.04%, beta of 1.22, and R² of 0.05 versus S&P 500 Index. Calculated based on daily prices since January 29, 2018.
- This stock participated in 220.01% of S&P 500 Index downside but only 108.40% of its upside — more exposed to losses than it benefited from rallies.
- R² of 0.05 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 4.04%
- Beta
- 1.22
- R²
- 0.05
- Upside Capture
- 108.40%
- Downside Capture
- 220.01%
Return for Risk
Risk / Return Rank
SLDB ranks 71 for risk / return — better than 71% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Solid Biosciences Inc. (SLDB) and compare them to a chosen benchmark (S&P 500 Index).
| SLDB | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.00 | 0.90 | +0.10 |
Sortino ratioReturn per unit of downside risk | 1.85 | 1.39 | +0.46 |
Omega ratioGain probability vs. loss probability | 1.23 | 1.21 | +0.02 |
Calmar ratioReturn relative to maximum drawdown | 1.50 | 1.40 | +0.10 |
Martin ratioReturn relative to average drawdown | 3.38 | 6.61 | -3.23 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore SLDB risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the Solid Biosciences Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Solid Biosciences Inc. was 99.76%, occurring on Oct 27, 2023. The portfolio has not yet recovered.
The current Solid Biosciences Inc. drawdown is 99.07%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.76% | Sep 21, 2018 | 1284 | Oct 27, 2023 | — | — | — |
| -78.32% | Mar 5, 2018 | 18 | Mar 28, 2018 | 57 | Jun 19, 2018 | 75 |
| -19.47% | Jun 26, 2018 | 3 | Jun 28, 2018 | 13 | Jul 18, 2018 | 16 |
| -17.72% | Feb 5, 2018 | 11 | Feb 20, 2018 | 3 | Feb 23, 2018 | 14 |
| -17.05% | Jun 20, 2018 | 1 | Jun 20, 2018 | 3 | Jun 25, 2018 | 4 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Solid Biosciences Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Solid Biosciences Inc. is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for SLDB in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, SLDB has a P/B value of 3.8. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |